中東和非洲經痛治療市場規模、份額和趨勢分析報告-產業概況和2032年預測

请求目录 请求目录 与分析师交谈 与分析师交谈 免费样本报告 免费样本报告 购买前请咨询 提前咨询 立即购买 立即购买

中東和非洲經痛治療市場規模、份額和趨勢分析報告-產業概況和2032年預測

  • Pharmaceutical
  • Published Report
  • Jan 2021
  • MEA
  • 350 页面
  • 桌子數: 231
  • 图号: 43

通过敏捷供应链咨询解决关税挑战

供应链生态系统分析现已成为 DBMR 报告的一部分

Middle East And Africa Menstrual Cramps Treatment Market

市场规模(十亿美元)

CAGR :  % Diagram

Chart Image USD 341.51 Million USD 720.96 Million 2024 2032
Diagram Forecast Period
2025 –2032
Diagram Market Size (Base Year)
USD 341.51 Million
Diagram Market Size (Forecast Year)
USD 720.96 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Pfizer Inc.
  • Johnson & Johnson
  • Bayer AG
  • Novartis AG
  • Sanofi S.A.

中東和非洲經痛治療市場細分,按類型(原發性經痛、繼發性經痛)、治療類型(藥物、熱療、生活方式改變、替代療法)、年齡組(青少年、成人)、最終用戶(醫院、診所、家庭護理機構)、分銷渠道(零售藥店、醫院藥店、網上藥店、其他)進行細分 - 行業趨勢及預測(至 2032 年)

中東和非洲經痛治療市場 Z

中東和非洲經痛治療市場規模

  • 2024 年中東和非洲經痛治療市場規模為 3.4151 億美元,預計到 2032 年將達到 7.2096 億美元,預測期內複合年增長率為 9.79%。
  • 市場成長主要源於該地區經痛等經期疾病的日益流行、經期健康意識的提升以及可支配收入和醫療保健支出的增加。不斷增長的女性人口,加上政府針對女性健康的措施和教育活動,是推動市場擴張的關鍵因素。
  • 此外,包括藥物療法和非藥物療法在內的治療方案的進步、遠距醫療和電子藥房的日益普及以及沙烏地阿拉伯和南非等中東和非洲國家醫療基礎設施的快速擴張,都在推動經痛治療的普及。這些因素共同作用,加速了各種治療方式的普及,顯著推動了中東和非洲經痛治療市場的成長。

中東和非洲經痛治療市場分析

  • 經痛,又稱經痛,是一種常見的婦科疾病,影響中東和非洲地區相當一部分女性。其療法多種多樣,從非處方止痛藥、荷爾蒙療法到生活方式的改變和替代療法,不一而足。人們對月經健康的認識日益提高,以及各種治療方式的普及,是推動該市場發展的關鍵因素。
  • 經痛治療需求的不斷增長,主要源於經痛盛行率的上升、人們對經期健康的認識不斷提高,以及對有效疼痛管理解決方案的需求日益增長。經痛治療以極低的副作用緩解疼痛,正日益受到個人和醫療保健提供者的青睞。
  • 目前,中東和非洲在經痛治療市場佔有相當大的份額,這得益於女性人口的成長、可支配收入的增加以及人們對月經健康的認識不斷提高。沙烏地阿拉伯引領著該地區的成長,這得益於醫療保健支出的增加、自我照護習慣的普及以及製藥商市場份額的不斷增長。
  • 預計在預測期內,南非將成為中東和非洲經痛治療市場中成長最快的國家,這得益於醫療保健服務可及性的改善、女性健康意識的增強以及對新型療法研發的投入增加。對自然療法和替代療法的需求不斷增長,進一步加速了該地區的成長。
  • 預計到2025年,「藥物」治療類型將佔據市場主導地位,佔據58%的市場份額,這得益於其在治療經痛方面的廣泛應用,尤其是非處方和處方止痛藥。這種治療方法可以快速緩解疼痛,通常是第一道防線,因此成為治療各種嚴重程度經痛的最常用方法。[AD1] 

報告範圍及中東及非洲經痛治療細分

屬性

中東和非洲經痛治療關鍵市場洞察

涵蓋的領域

  • 依類型:原發性經痛、繼發性經痛
  • 依治療類型:藥物治療、熱療、改變生活方式、替代療法
  • 依年齡層:青少年、成人
  •  依最終使用者:醫院、診所、居家照護機構
  • 按分銷管道:零售藥局、醫院藥局、網路藥局、其他

覆蓋國家

中東和非洲

  • 沙烏地阿拉伯
  •  阿聯酋
  •  南非
  • 埃及
  •  以色列
  • 中東和非洲其他地區

主要市場參與者

·輝瑞公司

· 強生公司

· 拜耳公司

· 諾華公司

· 賽諾菲公司

· 艾伯維公司

·梯瓦製藥工業股份有限公司

· 葛蘭素史克公司(GSK)

· 默克公司

· 歐加農

· 阿西諾

市場機會

  • 提高對月經健康解決方案的認識和接受度
  • 非藥物和天然療法的需求日益增長

加值資料資訊集

除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外,Data Bridge Market Research 策劃的市場報告還包括深入的專家分析、定價分析、品牌份額分析、消費者調查、人口統計分析、供應鏈分析、價值鏈分析、原材料/消耗品概述、供應商選擇標準、PESTLE 分析、波特分析和監管框架。

亞太地區經痛治療市場趨勢

          “非侵入性治療和家庭治療的採用日益增多”

  • 亞太地區經痛治療市場的一個重要且快速成長的趨勢是越來越多地使用非侵入性和家庭式解決方案,因為它們方便、經濟高效,而且女性對自我照護的偏好日益增長。
    • 例如,加熱墊和加熱貼等熱療產品越來越受到人們的青睞,尤其適用於慢性痛經和子宮內膜異位症相關疼痛等需要持續緩解和舒適感受的複雜病症。即使在日常活動中,它們也能有效緩解疼痛,這使其具有臨床優勢,尤其對職業女性和學生而言。
  • 此外,消費者越來越青睞草藥和膳食補充劑,而非傳統的止痛藥,尤其是在東亞和東南亞地區,因為越來越多的研究支持草藥和膳食補充劑的天然來源和更少的副作用。這對於人流量大的城市地區以及追求整體健康的個人尤其重要。
  • 在青少年和成年人群中,提供經皮神經電刺激 (TENS) 的可穿戴設備正被廣泛採用,以提供適合其年齡的疼痛緩解、最大程度地減少不適感,同時確保日常功能。製造商正透過謹慎的設計、可充電電池和智慧型手機連接來應對這項挑戰,以滿足日益增長的年齡多樣化患者群體的需求。
  • 這一趨勢也受到自我護理產品技術進步的推動,例如具有溫度感應功能的智慧型月亮杯和具有緩釋功能的止痛貼,這些產品可提高治療經痛的功效和使用者舒適度。

中東和非洲經痛治療市場動態

司機

“月經失調盛行率上升,健康意識增強”

  • 中東和非洲地區月經紊亂(包括經痛、子宮內膜異位症和多囊性卵巢症候群)的發生率激增,是經痛治療需求的主要驅動因素。隨著女性健康意識的增強和醫療保健服務可近性的提高,對安全、高效且隨時可用的疼痛管理解決方案的需求比以往任何時候都高。
  • 根據各地區健康調查和組織的調查,相當一部分女性人口患有經痛,這進一步證明了在常規和高級健康幹預期間進行有效治療的必要性。
  • 這些療法能夠快速緩解疼痛,有效控制症狀,並顯著降低副作用,使其成為全球女性的首選。這些特性能夠減輕不適,幫助女性更快恢復日常活動,並提高整體生活品質。
  • 此外,健康旅遊的成長和對預防性醫療保健的關注,尤其是在阿聯酋和南非等地區,正在推動對治療經痛的整體和自然療法的需求,這些療法可以帶來整體健康和長期益處。

克制/挑戰

“農村地區的文化恥辱和獲得專科護理的機會有限”

  • 儘管需求不斷增長,但由於不同社會群體對月經的文化污名化,市場仍面臨挑戰,這影響了人們對疼痛的公開討論和尋求適當治療。在一些發展中地區,由於獲得專業婦科護理的機會有限或缺乏對現有解決方案的了解,經痛要么被視為正常現象,要么得不到重視。
  • 此外,新興經濟體的女性對不同治療方法(例如荷爾蒙療法與傳統療法)的比較優勢缺乏了解,這阻礙了荷爾蒙療法的廣泛應用。由於對傳統療法的熟悉程度、成本敏感度或缺乏獲得先進醫療建議的途徑,女性可能會堅持使用傳統療法。
  • 供應鏈中斷、成本相關挑戰以及公共醫療系統缺乏新治療方案的報銷政策也限制了價格敏感市場的滲透。
  • 為了克服這些挑戰,主要參與者正專注於開展教育計畫、擴大區域分銷合作夥伴關係,並提供經濟高效的仿製藥替代品,以提高可及性。監管協調和本地化臨床試驗對於在尚未開發的地區擴大經痛治療藥物的市場覆蓋至關重要。

中東和非洲經痛治療市場範圍

 市場根據類型、治療類型、年齡層、最終用戶和分銷管道進行細分。

  • 按類型

 根據類型,中東和非洲經痛治療市場可分為原發性經痛和繼發性經痛。原發性經痛佔據市場主導地位,2024年其收入份額最高,達65.2%,這是因為原發性經痛在青少年和年輕女性中普遍存在,是一種常見的生理疾病。由於原發性經痛的普遍性,使其成為治療的重點,為常見的不適症狀提供便捷有效的解決方案。

繼發性經痛領域預計將在2024年至2032年間實現最快的複合年增長率,這得益於對子宮內膜異位症和子宮肌瘤等導致更嚴重和慢性疼痛的潛在疾病的診斷和治療需求的不斷增長。專科診所和先進診斷工具的日益普及也促使人們對繼發性經痛的關注度不斷提高,尤其是在城市醫院和先進的醫療中心。

  • 按治療類型

 根據治療類型,市場細分為藥物治療、熱療、生活方式改變和替代療法。預計藥物治療將佔據市場主導地位,收入份額最大,到2024年將達到48.9%,這得益於非處方止痛藥和處方激素療法的頻繁使用,這些療法可有效快速地緩解症狀。藥物治療通常用作日常疼痛的一線治療手段,兼顧了有效性和便利性。

隨著對自然、整體和非藥物疼痛管理方法的需求不斷增長,預計替代療法領域將在預測期內實現最快成長。此療法著重於整體健康,並最大程度降低副作用,尤其有助於長期管理和尋求補充解決方案的患者。

  • 按年齡組

根據年齡段,市場可分為青少年和成年人。由於育齡婦女中,有大量女性(包括患有潛在婦科疾病的女性)在整個生育期都會經歷經痛,因此成年人群體在2024年的市佔率最大,達到70.5%。

由於人們越來越關注青少年健康、年輕女孩及其父母的意識不斷增強,以及適合年齡的經痛治療方案的出現,預計青少年市場將在 2024 年至 2032 年間出現最快的複合年增長率。

  • 按最終用戶

 根據最終用戶,市場細分為醫院、診所和家庭護理機構。 2024年,家庭護理機構佔據了最大的收入份額,達到42.1%,這歸因於大量使用現成產品和療法自行管理經痛的病例。居家解決方案因其便利性、隱私性和成本效益而受到青睞,尤其適合常規疼痛管理。

預計醫院部門將實現最快的複合年增長率,這得益於尋求診斷和治療嚴重或複雜月經失調的女性數量不斷增加,以及使用專門幹預措施治療子宮內膜異位症和多囊性卵巢症候群等疾病。

  • 按分銷管道

 根據分銷管道,市場可細分為零售藥局、醫院藥局、線上藥局和其他。零售藥局佔據市場主導地位,預計到2024年將佔55.8%,這得益於非處方止痛藥和常用月經衛生用品的廣泛普及,使其成為消費者的主要購買管道。

預計線上藥局領域將在預測期內經歷最快的成長率,這得益於醫藥零售業的數位轉型、病患對送貨上門服務的偏好增加,以及線上訂購緩解經痛產品的便利性。

中東和非洲經痛治療市場區域分析

  • 中東和非洲在經痛治療市場佔據主導地位,2024 年的收入份額將達到 38.5%,這得益於該地區經痛盛行率的上升、女性健康意識的增強以及醫療保健基礎設施的不斷擴大。
  • 該地區的消費者和患者高度重視有效的疼痛管理,尤其是常見的經期不適。醫療保健可近性的改善、藥房和診所網絡的不斷擴張,以及現代和傳統療法的日益普及,促進了各種治療方法的推廣。
  • 政府的積極措施、對女性健康和保健的不斷投入,以及消費者對藥物和非藥物治療方案的日益青睞,進一步推動了經痛的廣泛應用。這些因素共同鞏固了中東和非洲在家庭護理和臨床治療領域經痛治療市場的領先地位。

沙烏地阿拉伯經痛治療市場洞察

2024年,沙烏地阿拉伯經痛治療市場在中東和非洲地區佔據了25.3%的顯著收入份額,這得益於快速的城市化進程、不斷增長的可支配收入以及對女性健康的高度關注。由於其在緩解普通經痛和嚴重經痛方面效果顯著,治療方案在沙烏地阿拉伯的醫療保健機構中越來越受歡迎。隨著中產階級人口的增長和私人醫療機構的擴張,對優質治療方案的需求也在增長。此外,本地生產能力的提升以及政府對醫療保健現代化的推動,也促進了經痛治療產品的普及和成本效益的提升。

南非經痛治療市場洞察

 由於南非醫療資源的不斷改善以及對有效疼痛管理需求的不斷增長,南非經痛治療市場正蓬勃發展。南非的醫療機構越來越多地採用各種療法,以快速緩解疼痛並提高患者的舒適度。不斷加強的監管環境,加上數位醫療和穿戴式裝置的技術創新,正在鼓勵人們使用高效且便利的治療方法。此外,南非女性對現代醫療保健和醫療保健安全性的文化偏好,使得各種治療方案都受到青睞。

阿聯酋經痛治療市場洞察

阿聯酋是中東地區醫療保健發展的重要樞紐,且患者群體不斷增長,預計其經痛治療市場將以12.5%的複合年增長率大幅增長。由於公共衛生運動的開展以及先進初級醫療保健服務覆蓋面的不斷擴大,阿聯酋民眾對月經健康的認識日益提升。對便利且價格合理的止痛產品的需求日益增長,加上女性人口不斷增長,對各種月經健康解決方案的需求持續增長,這些因素共同推動了有效治療方案的需求。此外,阿聯酋對遠距醫療和數位健康平台的重視也確保了市場的持續擴張。

中東和非洲經痛治療市場份額

中東和非洲經痛治療產業主要由知名公司主導,包括:

  • 輝瑞公司
  • 強生公司
  • 拜耳公司
  • 諾華公司
  • 賽諾菲公司
  • 艾伯維公司
  • 梯瓦製藥工業股份有限公司
  • 葛蘭素史克公司(GSK)
  • 默克公司
  • 奧加農
  • 阿西諾


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

4.1 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, PIPELINE ANALYSIS

5 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: REGULATIONS

6 PREMIUM INSIGHTS

6.1 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: ADOPTION RATE

6.1.1 DRIVERS AND BARRIERS FOR THE ADOPTIONS

6.2 MARKETING EXPENSES

6.3 PAYERS:

6.4 PHARMACIES COLD/HOT PADS MARKET SHARE:

7 EPIDEMIOLOGY

8 COVID-19 IMPACT ON MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET

8.1 PRICE IMPACT

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19

8.5 CONCLUSION

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 GROWING PREVALENCE OF DYSMENORRHEA

9.1.2 RISING TECHNOLOGICAL ADVANCEMENTS

9.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR DEVELOPING INNOVATIVE DRUGS AND THERAPIES

9.1.4 GOVERNMENT INITIATIVES WITH RESPECT TO WOMEN HEALTHCARE

9.1.5 INCREASING NUMBER OF TREATMENT OPTIONS

9.2 RESTRAINTS

9.2.1 PRODUCT RECALLS

9.2.2 LACK OF AWARENESS ABOUT REPRODUCTIVE HEALTH IN WOMEN

9.2.3 HIGH COST OF ENDOMETRIAL ABLATION AND HYSTERECTOMY

9.3 OPPORTUNITIES

9.3.1 RISE IN AWARENESS ABOUT DYSMENORRHEA

9.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS

9.3.3 RISING DISPOSABLE INCOME

9.4 CHALLENGES

9.4.1 TRADITIONAL FAMILY VALUE LEADING TO NO TREATMENT

9.4.2 SIDE EFFECTS AND COMPLICATIONS ASSOCIATED WITH LONG TERM TREATMENT

9.4.3 EFFECTIVENESS OF COMPLEMENTARY AND ALTERNATIVE THERAPIES

10 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE

10.1 OVERVIEW

10.2 PRIMARY DYSMENORRHEA

10.3 SECONDARY DYSMENORRHEA

11 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE

11.1 OVERVIEW

11.2 MEDICATION

11.2.1 FIRST LINE TREATMENT

11.2.1.1 Nonhormonal Therapy

11.2.1.1.1 Nonsteroidal Anti-Inflammatory Drugs

11.2.1.1.1.1 Ibuprofen

11.2.1.1.1.2 Naproxen

11.2.1.1.1.3 Celecoxib

11.2.1.1.1.4 Mefenamic Acid

11.2.1.1.1.5 Meclofenamate

11.2.1.1.2 Acetaminophen

11.2.1.2 Hormonal Replacement Therapy y

11.2.1.2.1 Combined Oral Contraceptives (Monophasic or Multiphasic)

11.2.1.2.1.1 Norethindrone/Ethinyl Estradiol

11.2.1.2.1.2 Extended-Cycle Oral Contraceptives

11.2.1.2.2 Extended-Cycle Oral Contraceptives

11.2.1.2.2.1 Levonorgestrel/Ethinyl Estradiol

11.2.1.2.2.2 Others

11.2.1.2.3 Other

11.2.1.2.3.1 Etonogestrel/Ethinyl Estradiol

11.2.1.2.3.2 Etonogestrel Implant

11.2.1.2.3.3 Levonorgestrel-Releasing Intrauterine System

11.2.1.2.3.4 Medroxyprogesterone Shot

11.2.1.3 Diuretic

11.2.1.3.1 Spironolactone

11.2.1.3.2 Ammonium Chloride

11.2.1.4 Antidepressants

11.2.2 SECOND LINE TREATMENT

11.2.2.1 Empiric GNRH Analogue or Antagonist Therapy

11.2.2.2 Ammonium Chloride

11.3 THERAPY

11.3.1 HEAT THERAPY

11.3.1.1 Patch

11.3.1.2 Wrap

11.3.1.3 Ceramic Belt Emitting Far-Infrared Radiation (FIR)

11.3.2 BEHAVIORAL COUNSELING

11.3.2.1 Desensitization-Based Procedures

11.3.2.2 Coping Strategies

11.3.2.3 Imagery

11.3.2.4 Hypnotherapy

11.3.2.5 Others

11.3.3 DIET AND VITAMINS

11.3.3.1 Vitamin E

11.3.3.2 Vitamin B

11.3.3.3 Vitamin D

11.3.3.4 Others

11.4 SURGERY

11.4.1 ENDOMETRIAL ABLATION

11.4.2 HYSTERECTOMY

11.5 OTHERS

12 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION

12.1 OVERVIEW

12.2 OVER THE COUNTER

12.3 PRESCRIPTION

13 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 ORAL

13.2.1 TABLETS

13.2.2 PILLS

13.2.3 CAPSULE

13.2.4 OTHERS

13.3 PARENTERAL

13.3.1 INTRAVENOUS

13.3.2 SUBCUTANEOUS

13.3.3 OTHERS

13.4 IMPLANTS

13.5 OTHERS

14 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 SPECIALTY CENTERS

14.4 AMBULATORY SURGICAL CENTERS

14.5 OTHERS

15 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 PHARMACIES

15.2.1 HOSPITAL

15.2.2 RETAIL

15.3 DIRECT TENDER

15.4 RETAIL SALES

15.5 OTHERS

16 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY GEOGRAPHY

16.1 MIDDLE EAST & AFRICA

16.1.1 SAUDI ARABIA

16.1.2 SOUTH AFRICA

16.1.3 UAE

16.1.4 ISRAEL

16.1.5 KUWAIT

16.1.6 EGYPT

16.1.7 REST OF MIDDLE EAST & AFRICA

17 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 GLAXOSMITHKLINE PLC.

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENTS

19.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANLYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENTS

19.4 ABBVIE INC.

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 MYLAN N. V. (A PART OF VIATRIS INC.).

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 PRODUCT PORTFOLIO

19.5.4 RECENT DEVELOPMENT

19.6 ALVOGEN

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 BAYER AG

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.7.4 RECENT DEVELOPMENTS

19.8 BEURER GMBH

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 BIOELECTRONICS CORPORATION

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 COLOR SEVEN CO., LTD.

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENTS

19.12 CUMBERLAND PHARMACEUTICALS INC.

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENTS

19.13 LIVIA

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENTS

19.14 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENTS

19.15 MYOVANT SCIENCES LTD.

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENT

19.16 NOBELPHARMA CO., LTD.

19.16.1 COMPANY SNAPSHOT

19.16.2 REVENUE ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENT

19.17 OBSEVA

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENTS

19.18 PFIZER INC.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENTS

19.19 PMS4PMS, LLC

19.19.1 COMPANY SNAPSHOT

19.19.2 PRODUCT PORTFOLIO

19.19.3 RECENT DEVELOPMENT

19.2 SANOFI

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENT

19.21 SUN PHARMACEUTICAL INDUSTRIES LTD.

19.21.1 COMPANY SNAPSHOT

19.21.2 REVENUE ANALYSIS

19.21.3 PRODUCT PORTFOLIO

19.21.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

表格列表

LIST OF TABLES

TABLE 1 MARKETING EXPENSES OF THE MARKET PLAYERS

TABLE 2 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA PRIMARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA SECONDARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 7 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 8 MIDDLE EAST & AFRICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA OVER THE COUNTER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA PRESCRIPTION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA IMPLANTS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2020-2028 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA HOSPITALS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA SPECIALTY CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA DIRECT TENDER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 MIDDLE EAST & AFRICA RETAIL SALES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 MIDDLE EAST & AFRICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 52 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 53 MIDDLE EAST & AFRICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 54 MIDDLE EAST & AFRICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 58 MIDDLE EAST & AFRICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 59 MIDDLE EAST & AFRICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 60 MIDDLE EAST & AFRICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 61 MIDDLE EAST & AFRICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 62 MIDDLE EAST & AFRICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 63 MIDDLE EAST & AFRICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 64 MIDDLE EAST & AFRICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 65 MIDDLE EAST & AFRICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 66 MIDDLE EAST & AFRICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 67 MIDDLE EAST & AFRICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 68 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 69 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 70 MIDDLE EAST & AFRICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 71 MIDDLE EAST & AFRICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 72 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 73 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 74 MIDDLE EAST & AFRICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 75 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 76 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 77 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 78 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 79 SAUDI ARABIA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 80 SAUDI ARABIA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 81 SAUDI ARABIA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 82 SAUDI ARABIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 83 SAUDI ARABIA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 84 SAUDI ARABIA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 85 SAUDI ARABIA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 86 SAUDI ARABIA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 87 SAUDI ARABIA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 88 SAUDI ARABIA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 89 SAUDI ARABIA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 90 SAUDI ARABIA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 91 SAUDI ARABIA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 92 SAUDI ARABIA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 93 SAUDI ARABIA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 94 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 95 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 96 SAUDI ARABIA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 97 SAUDI ARABIA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 98 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 99 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 100 SAUDI ARABIA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 101 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 102 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 103 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 104 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 105 SOUTH AFRICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 106 SOUTH AFRICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 107 SOUTH AFRICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 108 SOUTH AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 109 SOUTH AFRICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 110 SOUTH AFRICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 111 SOUTH AFRICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 112 SOUTH AFRICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 113 SOUTH AFRICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 114 SOUTH AFRICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 115 SOUTH AFRICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 116 SOUTH AFRICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 117 SOUTH AFRICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 118 SOUTH AFRICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 119 SOUTH AFRICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 120 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 121 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 122 SOUTH AFRICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 123 SOUTH AFRICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 124 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 125 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 126 SOUTH AFRICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 127 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 128 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 129 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 130 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 131 UAE MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 132 UAE FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 133 UAE NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 134 UAE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 135 UAE HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 136 UAE COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 137 UAE EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 138 UAE OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 139 UAE DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 140 UAE SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 141 UAE THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 142 UAE HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 143 UAE BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 144 UAE DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 145 UAE SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 146 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 147 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 148 UAE ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 149 UAE PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 150 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 151 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 152 UAE PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 153 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 154 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 155 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 156 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 157 ISRAEL MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 158 ISRAEL FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 159 ISRAEL NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 160 ISRAEL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 161 ISRAEL HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 162 ISRAEL COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 163 ISRAEL EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 164 ISRAEL OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 165 ISRAEL DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 166 ISRAEL SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 167 ISRAEL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 168 ISRAEL HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 169 ISRAEL BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 170 ISRAEL DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 171 ISRAEL SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 172 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 173 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 174 ISRAEL ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 175 ISRAEL PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 176 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 177 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 178 ISRAEL PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 179 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 180 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 181 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 182 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 183 KUWAIT MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 184 KUWAIT FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 185 KUWAIT NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 186 KUWAIT NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 187 KUWAIT HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 188 KUWAIT COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 189 KUWAIT EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 190 KUWAIT OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 191 KUWAIT DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 192 KUWAIT SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 193 KUWAIT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 194 KUWAIT HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 195 KUWAIT BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 196 KUWAIT DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 197 KUWAIT SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 198 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 199 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 200 KUWAIT ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 201 KUWAIT PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 202 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 203 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 204 KUWAIT PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 205 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 206 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 207 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 208 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 209 EGYPT MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 210 EGYPT FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 211 EGYPT NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 212 EGYPT NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 213 EGYPT HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 214 EGYPT COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 215 EGYPT EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 216 EGYPT OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 217 EGYPT DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 218 EGYPT SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 219 EGYPT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 220 EGYPT HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 221 EGYPT BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 222 EGYPT DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 223 EGYPT SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 224 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 225 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 226 EGYPT ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 227 EGYPT PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 228 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 229 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 230 EGYPT PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 231 REST OF MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

 

图片列表

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION

FIGURE 10 INCREASING PREVALENCE OF DYSMENORRHEA IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 11 PRIMARY DYSMENORRHEA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET IN 2021 & 2028

FIGURE 12 PHARMACIES COLD/HOT PADS MARKET SHARE: 2020 (%)

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET

FIGURE 14 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020

FIGURE 15 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)

FIGURE 16 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 17 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020

FIGURE 19 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020-2028 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2021-2028)

FIGURE 21 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, 2020

FIGURE 23 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION 2020-2028 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, CAGR (2021-2028)

FIGURE 25 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 27 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 29 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 30 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020

FIGURE 31 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 32 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, CAGR (2021-2028)

FIGURE 33 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 35 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 36 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 37 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: SNAPSHOT (2020)

FIGURE 39 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020)

FIGURE 40 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2021 & 2028)

FIGURE 41 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020 & 2028)

FIGURE 42 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE (2021-2028)

FIGURE 43 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY SHARE 2020 (%)

 

查看详细信息 Right Arrow

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息,请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析和主要(行业专家)验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息,请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制,包括目标品牌的价格趋势分析、了解其他国家的市场(索取国家列表)、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表(事实手册)中的数据,或者可以帮助您根据报告中的数据集创建演示文稿。

Frequently Asked Questions

市场是基于 中東和非洲經痛治療市場細分,按類型(原發性經痛、繼發性經痛)、治療類型(藥物、熱療、生活方式改變、替代療法)、年齡組(青少年、成人)、最終用戶(醫院、診所、家庭護理機構)、分銷渠道(零售藥店、醫院藥店、網上藥店、其他)進行細分 - 行業趨勢及預測(至 2032 年) 进行细分的。
在2024年,中東和非洲經痛治療市場的规模估计为341.51 USD Million美元。
中東和非洲經痛治療市場预计将在2025年至2032年的预测期内以CAGR 9.79%的速度增长。
市场上的主要参与者包括Pfizer Inc., Johnson & Johnson, Bayer AG, Novartis AG, Sanofi S.A., AbbVie Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Merck & Co.Inc., Organon, Acino 。
Testimonial